This cross-sector representation is central to advancing cancer research, innovation and precision medicine in Norway, and to strengthening links between science and commercial development, the cluster states.

New members

  • Sigbjørn Smeland, Head of the Division of Cancer Medicine at Oslo University Hospital
  • Tor Even Sogn Nergård, Executive Director for International Hematology at Eli Lilly
  • Tarje Bergdahl, Medical Director Norway at Novartis
  • Jens Petter Berg, Vice-Rector for Life Science and Health Research at the University of Oslo
  • Renée Amundsen, Chief Operating Officer at Lytix Biopharma
  • Ole Alexander Opdalshei, Deputy Secretary General at the Norwegian Cancer Society

Six members were re-elected, ensuring continuity in the board’s work: Line Bjørge (University of Bergen), Geir Hetland (Thermo Fisher Scientific), Gunhild Mari Mælandsmo (Oslo University Hospital), Thomas London (Oslo Science Hub) and Åsmund Flobak (St. Olavs Hospital/NTNU).

Jónas Einarsson, CEO of Radforsk and co-founder of Oslo Cancer Cluster, also retains a seat on the board as an honorary member.

Source: Oslo Cancer Cluster/Sofia Linden